Published on: January 10, 2026
The University Hospital of Clermont-Ferrand has announced a new clinical trial aimed at evaluating treatment options for dry and productive coughs. This research, which is not yet recruiting participants, will investigate two combination products, Group CDN and Group CW, to assess their effectiveness in managing cough symptoms. Clinical, regulatory, and quality professionals should stay informed as this development could impact therapeutic guidelines and device-related interventions.
What changed?
The University Hospital in Clermont-Ferrand has proposed a new clinical trial, focusing on two combination therapies, Group CDN and Group CW, for the treatment of coughs. While the trial is currently in the preparatory phase and not yet recruiting, it represents an important step in expanding treatment options for this common medical condition.
What are the details of the trial?
This upcoming trial aims to study the efficacy of two combination products for addressing coughs, both dry and productive. According to the information provided, the interventions will focus specifically on Group CDN and Group CW. Designed and supported by the University Hospital of Clermont-Ferrand, the study’s progress will likely be of interest to healthcare professionals involved in respiratory care and related sectors.
While specific details regarding the trial design, patient eligibility criteria, and outcome measures are currently unavailable, the fact that it has been registered under ClinicalTrials.gov suggests a commitment to robust, data-driven evaluation methods.
Stakeholders, including clinicians, regulatory advisors, and medical device professionals, should monitor updates for further information, especially around safety, effectiveness, and any regulatory submissions stemming from this investigation.
What are the implications for regulatory and clinical teams?
The treatment of coughs is a frequent focus in medical research due to its impact on patient quality of life and healthcare systems. If successful, this trial could influence prescription guidelines, therapeutic management strategies, and the future development or refinement of combination products for cough management.
From a regulatory perspective, projects like this may outline clearer pathways for the approval and implementation of combination therapies. Regulatory teams should pay close attention to updates as they could provide case studies or precedents valuable for future device submissions.
For clinical teams, a deeper understanding of these combination products could enhance decision-making processes for treating patients presenting with dry or productive coughs.
Frequently Asked Questions
1. Is the trial currently recruiting participants?
No, the trial is not yet recruiting.
2. What products are being evaluated?
The trial will investigate two combination products called Group CDN and Group CW.
3. Who is sponsoring the study?
The study is sponsored by the University Hospital, Clermont-Ferrand.
4. Where can I find more information?
Details have been published on ClinicalTrials.gov. See the link below for full information.
Conclusion
This upcoming clinical trial represents a significant opportunity to evaluate new combination therapies for cough management. Industry professionals, healthcare providers, and regulators alike should follow its progress closely. Additional updates from the University Hospital, Clermont-Ferrand, are expected as the recruitment phase begins and further development milestones are reached.
Disclaimer
This article provides information intended for healthcare and regulatory professionals. It is not legal, clinical, or regulatory advice. Please consult appropriate professionals for guidance specific to your needs.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07330856?term=medical+device